OMTX005 (OMTX705 antibody) is a humanized anti- FAP IgG1 monoclonal antibody that specifically binds to human ( EC 50: 0.33 nM)/mouse ( EC 50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research [1].
In Vitro, OMTX005 specifically binds to FAP-expressing HT1080-FAP cells and primary CAF07 cells, with EC50 values of 76 pM and 130 nM, respectively[1]. OMTX005 (5 days) does not reduce the viability of HT1080-WT, HT1080-FAP or primary CAF07 cells[1]. OMTX005 (400 nmol/L; 0-48 h) does not induce caspase 3/7 activity in HT1080-WT, HT1080-FAP or primary CAF07 cells[1].
References:
[1]. Fabre M, et al. OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clin Cancer Res. 2020;26(13):3420-3430.
In Vitro, OMTX005 specifically binds to FAP-expressing HT1080-FAP cells and primary CAF07 cells, with EC50 values of 76 pM and 130 nM, respectively[1]. OMTX005 (5 days) does not reduce the viability of HT1080-WT, HT1080-FAP or primary CAF07 cells[1]. OMTX005 (400 nmol/L; 0-48 h) does not induce caspase 3/7 activity in HT1080-WT, HT1080-FAP or primary CAF07 cells[1].
References:
[1]. Fabre M, et al. OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clin Cancer Res. 2020;26(13):3420-3430.